Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Amphastar Pharmaceuticals Q3 2026 Results: Net Income $37.8M, Up 117.7% YoY

Amphastar Pharmaceuticals reported total assets of $1.71 billion as of September 30, 2026, up from $1.63 billion at year-end 2025. The company maintained a strong liquidity position with $204.6 million in cash and cash equivalents, while total liabilities increased to $897.2 million, primarily driven by long-term debt and operating lease liabilities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue207.6191.8
Gross profit99.698.6
Profit before tax49.121.5
Net income37.817.4
EPS (diluted, $ a share)$0.87$0.37

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+117.7%
Revenue, year on year+8.2%
Gross margin48.0%
Operating margin24.5%
Source

10-Q filed with the SEC, NASDAQ: AMPH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Amphastar Pharmaceuticals, Inc.: key numbers

Share price
$29.17Close, Nov 16
Market cap
$1.24B
Shares outstanding
42.65MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Amphastar Pharmaceuticals, Inc.

All →
4:32 PM ET 8-K
Financial Results

Amphastar Pharmaceuticals Financial Results

Amphastar Pharmaceuticals reported third quarter 2026 net revenues of $207.6 million, an 8% increase year-over-year driven by record sales of BAQSIMI and Primatene MIST. The company achieved GAAP net income of $37.8 million, or $0.87 per diluted share, significantly up from $17.4 million in the prior year period.

Term
3 months

“Our third quarter results demonstrate the strength of Amphastar’s diversified portfolio and the commercial platform we have built. Record sales of BAQSIMI® and Primatene MIST®, together with contributions from recently launched products, supported continued revenue growth and further strengthened the foundation for our long-term strategy.”

Dr. Jack Zhang, Amphastar’s President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.